Thursday, November 23, 2017

Integrated BioSci Investing: A 2017 Thanksgiving Note


  • Our marketplace is growing to deliver increasing value to subscribers.
  • Spectrum Pharmaceuticals is the top performer. Second comes Nektar Therapeutics. Our portfolio is also powered by many other key winners.
  • Kite Pharma was bought out in the recent months.
  • We wish to send our Happy Thanksgiving to all readers, subscribers, and SA.
  • Subscribe to our marketplace service to receive higher level intelligence, to galvanize your portfolio.

For the past 52-weeks, the Biotechnology Index (NASDAQ:IBB) gained 9.75% while key performers in our Integrated BioSci Investing portfolio posted profits far more robust. Kite Pharma (NASDAQ:KITE), now a subsidiary of Gilead Sciences (NASDAQ:GILD) delivered over 247% returns. Spectrum Pharmaceuticals (NASDAQ:SPPI) appreciated over 361%. Nektar Therapeutics (NASDAQ:NKTR) headed north over 250%. And, Amicus Therapeutics (NASDAQ:FOLD) procured over 51% profits.

Source: Google Finance (Notable Small-Caps BioSci Winners)
In 2013, we joined the ride with Seeking Alpha (and in May 2017, we decided to exclusively focus on our bioscience expertise). Since the commencement of our marketplace service (Integrated BioSci Investing) in the past five months, our overall recommendations to subscribers have been highly profitable (especially with key performers, as mentioned above).

For Thanksgiving 2017, we wish to send our appreciation to all readers (and especially subscribers as well as Seeking Alpha) for your readership, friendship, advice, and business. There are many highly intelligent subscribers, who enjoy the mutual learning. Going forward, we hope to continue to deliver our stellar service to you. Thank you all, and Happy Thanksgiving!